How Kohli was paid
$1.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Total |
|---|---|---|---|---|
| Prashant KohliChief Executive Officer | $500,000 | $324,621 | $250,000 | $1,074,621 |
| Amresh KumarVice President, Program Management | $286,000 | $49,763 | $85,800 | $421,563 |
| Carrie D’AndreaVice President, Clinical Operations | $286,000 | $49,763 | $85,800 | $421,563 |
What changed and why
- $1.1M$1,074,621 CEO total compensation in 2025 compared with $987,630 in 2024.
- $325K$324,621 CEO option award was granted with a $2.96 exercise price and three-year quarterly vesting.
- 50%50% CEO target bonus was paid at 100% of target based on corporate objectives.
- $250K$250,000 CEO performance bonus reflected completion of corporate milestones related to the Phase 3 STRIVE ON trial.
- 30%30% target bonuses applied to the other named executives, with each receiving $85,800.
- 12 months of base salary is payable to the CEO after termination without Cause, subject to a release.
Other Grace Therapeutics proxy statements
- 2026 proxy statement
Prashant Kohli paid $1.3M (+17% on the year).
Filed Jul 28, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.